Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinamide 8-bromo‐adenine dinucleotide phosphate (NA8BrADP) is a synthetic analog of nicotinamide adenine dinucleotide phosphate (NADP+), which is an essential cofactor in many enzymatic redox reactions. The compound features a brominated adenine moiety at the eighth position. As an NADP+ analog and member of the (5'→5')‐dinucleotides class of organic compounds, it may be used experimentally to probe or modulate NADP+-dependent biochemical pathways or enzyme activities. There are no approved therapeutic indications for this molecule; it is classified as experimental and primarily used in research settings[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide 8-bromo-adenine dinucleotide phosphate.